Nov 4
Sponsors Collect Too Much “Non-Essential” Data, Say Tufts And TransCelerate
11/06/2025
Over the last 10 years, both clinical trial procedures and data points collected have skyrocketed, and everyone’s noticing. The last decade has brought a 40% increase in total procedures and a 283% increase in data points collected during Phase 3 pivotal trials, according to a paper presentation by Getz et al.
Read the full article by Clinical Leader here.
Related Blog Posts
TransCelerate Highlights Digital Momentum and Global Collaboration in 2025 Annual Report
TransCelerate BioPharma has released its 2025 annual report, titled The Power of Forward, outlining a year defined by continued digital adoption, regulatory collaboration, and expansion of pragmatic approaches to clinical development. Read the full article featuring Janice Chang from Applied Clinical Trials here.
When Friction Meets Force in Clinical Research
More than a decade ago, a group of pharma R&D heads gathered for an annual meeting focused on addressing common industry challenges. They had a running joke: With an average tenure of just three years, if they wanted to see each other at more than one of these gatherings, they’d better figure out how to…
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines. Read the full article featuring Rob DiCicco from Citeline here.